Nintedanib dry powder inhalation therapy has favorable safety, tolerability in IPF

Nintedanib dry powder inhalation in patients with idiopathic pulmonary fibrosis was “generally safe” with “a tolerability profile built for chronic use,” according to topline data from a phase 1b study.“There’s an urgent need for new effective therapies in IPF, and we believe lung targeted delivery is the best approach that addresses the tolerability barriers